# Bundibugyo ebolavirus

Type: pathogen

Source: GetYourBrief — https://getyourbrief.com/entity/bundibugyo-ebolavirus
Canonical HTML page: https://getyourbrief.com/entity/bundibugyo-ebolavirus

## Timeline

- **2026-07-13**: Ethics Approval Received — NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
- **2026-07-13**: Ethics Approval Received — NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
- **2026-07-12**: Outbreak Worsens — DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
- **2026-07-12**: Outbreak Worsens — DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
- **2026-07-10**: Africa CDC declares fastest-growing outbreak — Africa CDC states the outbreak is the fastest-growing Ebola epidemic on the continent as news of the spread to new provinces circulates.
- **2026-07-09**: Health workers protest — Ebola response workers protest outside three treatment centers in Bunia over unpaid wages; police disperse one demonstration at CME.
- **2026-07-08**: Government report released — A government report published late Wednesday confirms 1,759 total cases and 600 deaths, with two new suspected cases in Kisangani, Tshopo province—one with no known epidemiological link.
- **2026-07-03**: Clinical trials scheduled — Health workers prepare for Ebola clinical trials at the Evangelical Medical Center in Bunia, Ituri province.
- **2026-05-15**: Outbreak declared — DRC authorities declare a new Ebola outbreak caused by the Bundibugyo virus, after weeks of undetected transmission according to WHO.

## Recent coverage (3 stories, network-wide)

### 1,926 Ebola Cases and 702 Deaths: Could Oral Gummies Change Outbreak Response?
2026-07-13 19:35:12 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

As the DRC Ebola outbreak surpasses 1,900 cases with 702 fatalities, NanoViricides’ oral NV-387 gummies gain ethics approval for a Phase II trial. The chewable format could overcome logistical hurdles in resource-limited regions, potentially reshaping epidemic management if proven effective.
Full story: https://gethealthbrief.com/story/ebola-oral-gummies-phase2-public-health

### NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender
2026-07-13 19:35:03 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
Full story: https://getbiobrief.com/story/nanoviricides-nnvc-oral-ebola-phase2

### Congo Ebola Outbreak: 600 Dead, New Cases Spread to Two Provinces
2026-07-11 23:25:15 · Sector: health · Sentiment: Strongly negative · Impact: 8/10 · Sources: 5

The public health crisis deepens as Ebola spreads to previously unaffected areas, with response hampered by funding gaps, worker protests, and no approved countermeasures.
Full story: https://gethealthbrief.com/story/congo-ebola-outbreak-600-dead-spread

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.